NASDAQ: IBRXImmunitybio Inc Stock
$2.64-0.06 (-2.22%)
Updated Jun 30, 2025
IBRX Price
$2.64
Fair Value Price
N/A
Market Cap
$2.33B
52 Week Low
$1.83
52 Week High
$7.48
P/E
-4.89x
P/B
-3.94x
P/S
82.25x
PEG
N/A
Dividend Yield
N/A
Revenue
$31.22M
Earnings
-$409.10M
Gross Margin
99.8%
Operating Margin
-844.37%
Profit Margin
-1,310.3%
Debt to Equity
-1.51
Operating Cash Flow
-$370M
Beta
2.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IBRX Overview
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IBRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important IBRX news, forecast changes, insider trades & much more!
IBRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IBRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IBRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IBRX due diligence checks available for Premium users.
Valuation
IBRX fair value
Fair Value of IBRX stock based on Discounted Cash Flow (DCF)
Price
$2.64
Fair Value
-$3.18
Undervalued by
182.97%
IBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.89x
Industry
-123.86x
Market
32.47x
IBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.94x
Industry
4.44x
IBRX's financial health
Profit margin
Revenue
$16.5M
Net Income
-$129.6M
Profit Margin
-784.9%
IBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IBRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$303.8M
Liabilities
$894.2M
Debt to equity
-1.51
IBRX's short-term assets ($109.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IBRX's long-term liabilities ($845.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$85.9M
Investing
$4.1M
Financing
-$982.0k
IBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IBRX vs Biotech Stocks
Immunitybio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.